← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Oyagen, Inc.
Rochester, NY
$6,756,704
Total funding
9
Grants
Funding over time
peak $1M · FY2009–24$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,756,704 · 9
By mechanism
R01$3,159,365 · 2
R43$2,369,862 · 4
R21$1,227,477 · 3
Investigators at Oyagen, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Discovery of Chemical Probes for RNA-Binding Protein Host Defense Factors$605,606
R01 · FY2016 · GM
Discovery of Chemical Probes for RNA-Binding Protein Host Defense Factors$601,514
R01 · FY2015 · GM
Discovery of Chemical Probes for RNA-Binding Protein Host Defense Factors$560,451
R01 · FY2017 · GM
Identification of Antagonists of the Molecular Chaperone Function of CBF beta$468,483
R01 · FY2013 · GM
Identification of Antagonists of the Molecular Chaperone Function of CBF beta$439,233
R01 · FY2015 · GM
Identification of Antagonists of the Molecular Chaperone Function of CBF beta$439,233
R01 · FY2014 · GM
Binding Interface of HIV Vif and APOBEC3G as a Therapeutic Target$403,638
R21 · FY2016 · AI
IND-Enabling Development of a Small Molecule COVID Therapeutic$300,000
R43 · FY2024 · AI
Preclinical Development of HIV Vif Antagonists$300,000
R43 · FY2019 · AI
IND-Enabling Development of a Small Molecule COVID Therapeutic$300,000
R43 · FY2023 · AI
Preclinical Development of HIV Vif Antagonists$300,000
R43 · FY2018 · AI
High throughput screening and drug discovery for antagonists of the Ebola VP40 protein assembly$299,000
R43 · FY2023 · AI
High throughput screening and drug discovery for antagonists of the Ebola VP40 protein assembly$298,000
R43 · FY2024 · AI
Development of Lead Inhibitors of HIV Vif Binding to Antiretroviral A3G Through Medicinal Chemistry$286,431
R43 · FY2020 · AI
Development of Lead Inhibitors of HIV Vif Binding to Antiretroviral A3G Through Medicinal Chemistry$286,431
R43 · FY2021 · AI
Development of a Novel HIV/AIDS Therapeutic Activating the APOBEC3G Host Defense$252,000
R21 · FY2011 · AI
Development of a Novel HIV/AIDS Therapeutic Activating the APOBEC3G Host Defense$210,000
R21 · FY2012 · AI
Binding Interface of HIV Vif and APOBEC3G as a Therapeutic Target$200,879
R21 · FY2017 · AI
Development of a High Throughput Screen for Antagonists of Vif Dimerization$128,710
R21 · FY2009 · NS
Identification of Antagonists of the Molecular Chaperone Function of CBF beta$44,845
R01 · FY2014 · GM